Spots Global Cancer Trial Database for selpercatinib

Every month we try and update this database with for selpercatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	NCT04211337	Medullary Thyro...	Selpercatinib Cabozantinib Vandetanib	12 Years -	Eli Lilly and Company
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	NCT04759911	Malignant Thyro... Poorly Differen... Recurrent Thyro... Thyroid Gland A... Thyroid Gland M... Thyroid Gland P... Thyroid Gland S...	Quality-of-Life... Questionnaire A... Selpercatinib Therapeutic Con...	12 Years -	M.D. Anderson Cancer Center
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	NCT03157128	Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor	LOXO-292	12 Years -	Eli Lilly and Company
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer	NCT05364645	Lung Non-Small ... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Carboplatin Pemetrexed Selpercatinib	18 Years -	SWOG Cancer Research Network
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	NCT04194944	Non-Small Cell ...	Selpercatinib Carboplatin Cisplatin Pemetrexed Pembrolizumab	18 Years -	Eli Lilly and Company
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	NCT04194944	Non-Small Cell ...	Selpercatinib Carboplatin Cisplatin Pemetrexed Pembrolizumab	18 Years -	Eli Lilly and Company
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	NCT03906331	Non Small Cell ... Medullary Thyro... Colon Cancer Breast Cancer Pancreatic Canc... Papillary Thyro... Other Solid Tum...	Selpercatinib	18 Years -	Eli Lilly and Company
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04320888	Hematopoietic a... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Lymph... Recurrent Malig... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent WHO G... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Lymp... Refractory Mali... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory WHO ... Wilms Tumor	Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Selpercatinib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation	NCT04280081	Solid Tumor Medullary Thyro...	Selpercatinib	18 Years -	Eli Lilly and Company
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	NCT05668962	Thyroid Cancer Thyroid Carcino... Metastatic Thyr... Follicular Thyr... Unresectable Th... Papillary Thyro...	Selpercatinib Sodium Iodine I... rhTSH	12 Years -	Massachusetts General Hospital
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy	NCT04591431	Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer	Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib	18 Years -	Fondazione per la Medicina Personalizzata
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	NCT05159245	Advanced Cancer Solid Tumor Haematological ...	Alectinib Cobimetinib Vismodegib Trastuzumab+Per... Entrectinib Atezolizumab Vemurafenib Regorafenib Apalutamide Abemaciclib Selpercatinib Dabrafenib Trametinib Dabrafenib+Tram... Pralsetinib	18 Years - 100 Years	Helsinki University Central Hospital
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)	NCT04819100	Carcinoma, Non-...	Selpercatinib Placebo	18 Years -	Eli Lilly and Company
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	NCT04759911	Malignant Thyro... Poorly Differen... Recurrent Thyro... Thyroid Gland A... Thyroid Gland M... Thyroid Gland P... Thyroid Gland S...	Quality-of-Life... Questionnaire A... Selpercatinib Therapeutic Con...	12 Years -	M.D. Anderson Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	NCT03155620	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Histiocytic Sar... Juvenile Xantho... Langerhans Cell... Malignant Gliom... Recurrent Child... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Ensartinib Erdafitinib Laboratory Biom... Larotrectinib S... Magnetic Resona... Mutation Carrie... Olaparib Palbociclib Pharmacological... Positron Emissi... Radionuclide Im... Samotolisib Selpercatinib Selumetinib Sul... Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)	NCT03944772	Non-Small Cell ...	Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der...	18 Years - 130 Years	AstraZeneca

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: